LONDON, March 2 (Reuters) - Britain's Alizyme Plc (AZM.L: Quote, Profile, Research) said its experimental treatment for mucositis, a side-effect of chemotherapy, had passed an intermediate clinical trial, sending its shares almost 9 percent higher on Thursday.
